Matt Sause

New Capabilities

Active

A biopsy from the lining of a lung can look like several diseases under a microscope: mesothelioma, non-small cell lung cancer, or a benign scar. Roche's new BAP1 test uses a single marker with near-perfect specificity to isolate the deadliest possibility, malignant mesothelioma, from the rest.

Updated Oct 31

Money Moves

As of May 2026: Leading the integration of PathAI into Roche's Diagnostics division

For a century, the cancer diagnosis that decides a patient's treatment has come from a pathologist staring at a tumor slide through a microscope. Software is now doing that reading—and the pharmaceutical companies that sell the drugs are buying the companies that built the software. On May 7, Roche agreed to pay up to $1.05 billion for PathAI, the largest independent AI pathology firm in the United States.

Updated May 31